4.7 Article

Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability

期刊

INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 423, 期 2, 页码 554-561

出版社

ELSEVIER
DOI: 10.1016/j.ijpharm.2011.11.035

关键词

Doxorubicin hydrochloride; Lipid nanocarrier; Gantrez; Lipomer; Drug loading; Oral bioavailability

资金

  1. University Grants Commission, Govt. of India

向作者/读者索取更多资源

The present study discusses design of doxorubicin hydrochloride (Dox) loaded lipid based nanocarrier (LIPOMER) for oral delivery. High entrapment (>90%) and high loading (38.11 +/- 0.37% w/w) of hydrophilic Dox in lipid nanocarrier of polyglyceryl-6-distearate was achieved using poly(methyl vinyl ether-co-maleic anhydride) (Gantrez (R) AN 119) and a modified nanoprecipitation method. Dox-LIPOMER revealed nanosize (314 +/- 16.80 nm) and negative zeta potential (-25.00 +/- 2.41 mV). Dox-LIPOMER exhibits sustained release in vitro and was influenced by ionic strength of dissolution medium. DSC and XRD studies suggested amorphous nature of Dox in LIPOMER. TEM revealed spherical morphology of Dox-LIPOMER. Dox-LIPOMER was stable up to 12 months at 25 degrees C/60% RH. A 384% enhancement in oral bioavailability compared to Dox solution was observed following Dox-LIPOMER administration at 10 mg/kg body weight. Superoxide dismutase (SOD), catalase (CAT) and malondialdehyde (MDA) assay data of heart and kidney tissues of rats treated with Dox-LIPOMER were comparable with untreated rats. Dox-LIPOMER represents a potential safe drug delivery system for oral administration. (C) 2011 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据